EUVIMED · CrossrefJournal
Hepatology
ISSN 0270-9139 · Ovid Technologies (Wolters Kluwer Health)
Latest articles
Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH
Combined HDV RNA and anti-HDV measurement for the management of HBV/HDV coinfection
BMN 349, a small molecule inhibitor of Z alpha-1 antitrypsin polymerization, increases secretion and reduces intrahepatic inclusions in a mouse model of disease
Noncontrast abbreviated MRI demonstrates superior diagnostic accuracy compared to ultrasound for hepatocellular carcinoma detection: Interim results from a prospective surveillance trial
Vitamin E dosing study (VEDS) in patients with metabolic dysfunction–associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial
Metabolic reprogramming of the tumor microenvironment during transarterial therapy: Where no catheter has gone before
H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis
Turning the page: Reflecting with gratitude and welcoming new chapters
Two drugs, one liver: A real-world test of GLP-1 RA and SGLT-2i combination therapy in MASLD
A common thread in autoimmunity: IL12 links AIH and PBC to systemic disease
Stepping up liver care: Rethinking alcohol treatment in chronic liver disease
How low can you go? Is lower-dose vitamin E effective and safe for MASH?
Erratum: Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma
2026 Reviewers (Volumes 83 and 84)
The DARk side of aspartyl-tRNA synthetase 1 (DARS1): From tRNA aminoacylation to driver of liver cancer
Hyperammonaemia is associated with hospitalisation for bacterial infection: A multicentre cohort study
Digital pathology in hepatocellular carcinoma: From prognostic prediction to biological understanding and precision medicine
Remote patient management reduces liver-related hospitalizations in patients with acutely decompensated cirrhosis
AASLD EXPO: Diagnosis and management of hepatitis delta virus (HDV) infection
Introducing Michael Ronan Lucey, MD, the 78th President of AASLD
2026 Late Breaking Abstracts
Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial
ATTEST 2027: A Framework for AI Transparency Tiered by Evidentiary Stakes
MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease
Hepatectomy alters adjuvant anti–PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages
Volumes
2026 · 4532025 · 5292024 · 3972023 · 4972022 · 5432021 · 7022020 · 5322019 · 6122018 · 6362017 · 6102016 · 7232015 · 6792014 · 7142013 · 7322012 · 5882011 · 6242010 · 7452009 · 6682008 · 6322007 · 5382006 · 4732005 · 4652004 · 5432003 · 1,9122002 · 5932001 · 4552000 · 4511999 · 5191998 · 5111997 · 9121996 · 1,1101995 · 2,9271994 · 1,3771993 · 2,1111992 · 5191991 · 9131990 · 4481989 · 3941988 · 3241987 · 304
EUVIMED